Core Insights - The collaboration between NetraMark Holdings Inc. and Fondazione per la Medicina Personalizzata (FMP) aims to analyze the ROME Phase II oncology trial dataset using NetraMark's NetraAI platform to identify clinically actionable insights for precision oncology strategies [1][5][7] Group 1: Collaboration Details - NetraMark will utilize its proprietary NetraAI platform to analyze the ROME dataset and other oncology datasets provided by FMP, focusing on uncovering clinically meaningful patient subpopulations and biomarker-driven treatment patterns [5][7] - The initial phase of the collaboration will concentrate on discovering and validating high-signal patient subgroups within the ROME dataset, with potential subsequent phases including tumor-specific analyses and evaluations of treatment modalities [6][7] Group 2: ROME Trial Overview - The ROME trial is a multicenter, randomized, open-label Phase II study that compares tailored treatment to standard care for patients with advanced solid tumors, guided by comprehensive genomic profiling [3][4] - In the intention-to-treat population of 400 randomized patients, the trial reported improvements in overall response rate and progression-free survival for tailored treatment compared to standard care, while overall survival was similar due to a high crossover rate [4] Group 3: Strategic and Clinical Value - The collaboration is expected to generate long-term value by combining FMP's oncology datasets with NetraAI's analytical capabilities, which may enhance future clinical trial design, biomarker development, and patient stratification strategies [7][8] - The goal is to identify Model-Derived Subgroups (MDS) that reveal underlying disease structures and treatment-response dynamics across key clinical endpoints [5][6] Group 4: NetraAI Technology - NetraAI is designed to separate small datasets into explainable and unexplainable subsets, potentially increasing the likelihood of clinical trial success by avoiding overfitting and deriving actionable insights [10][11] - The platform's unique focus mechanisms allow for accurate segmentation of patient data, enhancing the ability to classify patients based on sensitivity to drugs and treatment efficacy [11]

Core Viewpoint - Inscobee Inc. and Apimeds, Inc. have taken decisive actions to restructure the board of Apimeds Pharmaceuticals US, Inc. following a written consent from majority stockholders, which has led to a dispute with MindWave Innovations Inc. regarding the validity of these actions [2][3][4]. Group 1: Board Restructuring - On March 20, 2026, Inscobee and Apimeds Korea, along with other stockholders, delivered a written consent to remove four directors from the board of Apimeds Pharmaceuticals US, Inc. [2] - The majority stockholders appointed three new directors and reduced the board size to three members, also removing the CEO and CFO of the Company [2]. - Mr. Youngjik Cho was appointed as the new CEO of the Company following the board restructuring [2]. Group 2: Dispute with MindWave Innovations - MindWave issued a press release challenging the actions taken by Inscobee and Apimeds Korea, alleging a breach of the Support Agreement and threatening litigation [3]. - Inscobee and Apimeds Korea strongly disagree with MindWave's allegations, asserting that the written consent is valid and does not violate the Support Agreement [4]. - The companies maintain that their actions are within the legal framework provided by Delaware General Corporate Law, which allows for the removal of directors by a majority of voting power [6]. Group 3: Background on the Merger - Apimeds Korea and Inscobee had previously engaged in discussions regarding a merger that made MindWave a wholly owned subsidiary, but faced challenges in obtaining information about MindWave's ownership of critical digital assets, specifically 1,000 bitcoin [5]. - The companies assert that the actions taken in the written consent are not in violation of any irrevocable proxy granted under the Support Agreement [6].

Core Insights - C4 Therapeutics has initiated a Phase 1b trial for cemsidomide, an oral IKZF1/3 degrader, in combination with elranatamab for treating relapsed/refractory multiple myeloma [1][2] Company Overview - C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation science, aiming to develop innovative therapies for difficult-to-treat diseases [9] - The company utilizes its TORPEDO platform to design and optimize small-molecule medicines [9] Product Development - Cemsidomide is an investigational oral molecular glue degrader targeting IKZF1/3, which are critical transcription factors in multiple myeloma biology [4] - The Phase 1b trial will evaluate the safety, tolerability, and preliminary efficacy of cemsidomide in combination with elranatamab, with an enrollment of up to 54 patients [2][5] - The trial will start with a dose of 75 µg of cemsidomide, with the possibility to explore 50 µg and 100 µg doses [2][5] Clinical Trials - The Phase 1b trial is part of a broader strategy to support cemsidomide's use across multiple treatment lines, including the ongoing Phase 2 MOMENTUM trial [3] - The MOMENTUM trial is designed to evaluate cemsidomide in combination with dexamethasone in patients who have received at least three prior anti-myeloma regimens [7] Market Context - Multiple myeloma is a rare blood cancer with approximately 36,000 new diagnoses in the U.S. each year, highlighting the need for new therapeutic options [8] - IKZF1/3 degraders are foundational therapies in multiple myeloma treatment, and there is a growing demand for innovative therapies that enhance T-cell activation and myeloma cell death [8]

Core Viewpoint - Algernon Health Inc. has launched a new brand name, NovaScan Neuroimaging Clinics, for its network of brain PET scanning centers in the U.S., featuring the FDA-cleared CareMiBrain™ system, which is a standalone PET scanner without an integrated CT component [1][6]. Company Overview - Algernon Health is a Canadian healthcare company focused on providing brain-specific PET scanning services through a planned network of neuroimaging clinics in the U.S. aimed at early-stage detection of Alzheimer's Disease and other neurological conditions [10]. Brand Identity - The new brand name, NovaScan, combines "Nova," meaning 'new' in Latin, and "Scan," reflecting the company's vision for a streamlined approach to brain PET imaging [4]. - The visual identity features navy and red fonts symbolizing American heritage, with a logo designed to represent the shape of a brain, emphasizing cognitive health and patient comfort [5]. Technology and Services - The CareMiBrain™ technology allows for 25% less radiation exposure to patients compared to traditional PET/CT scanners, as it operates independently without a CT component [7]. - The Florida clinic will be the first in the U.S. to provide dedicated brain-optimized PET scans, aiding in the detection and treatment of Alzheimer's Disease and other neurological disorders [6]. Future Plans - The inaugural clinic is located at the HCA Florida University Medical Offices in Davie, approximately twenty minutes southwest of Fort Lauderdale, with updates on the official opening date and patient referrals expected soon [9].

Core Insights - Maze Therapeutics reported positive topline data from the Phase 2 HORIZON trial of MZE829, demonstrating clinical proof-of-concept in patients with broad APOL1-Mediated Kidney Disease (AMKD) [1][3] - The company plans to advance MZE829 into a pivotal program and initiate two Phase 2 trials for MZE782 in phenylketonuria (PKU) and chronic kidney disease (CKD) by 2026 [2][4] - Neil Kumar, Ph.D., has been appointed to the Board of Directors, bringing valuable experience from BridgeBio [2][6] Program Progress and Anticipated Milestones - MZE829 is an oral, small molecule APOL1 inhibitor targeting AMKD, which affects over one million people in the U.S. [3] - The Phase 2 HORIZON trial showed a mean reduction in proteinuria of 35.6% at week 12, with 50% of patients achieving over a 30% reduction [3] - In patients with severe focal segmental glomerulosclerosis (FSGS), the mean reduction in proteinuria was 61.8% [3] - MZE782 targets the solute transporter SLC6A19, with potential applications in PKU and CKD, with trials expected to start by mid-2026 [4] Financial Highlights - As of December 31, 2025, Maze had $360.0 million in cash, cash equivalents, and marketable securities, up from $196.8 million in 2024, providing a cash runway into 2028 [9][21] - Research and development expenses for 2025 were $108.4 million, an increase from $83.5 million in 2024, primarily due to higher clinical trial costs [11] - General and administrative expenses rose to $34.5 million in 2025 from $26.4 million in 2024, reflecting increased personnel-related costs [12] Recent Corporate Developments - The appointment of Neil Kumar to the Board is expected to enhance the company's strategic direction and growth potential [2][6] - Maze achieved a $20 million milestone in its collaboration with Shionogi & Co., Ltd. for MZE001, with potential additional milestone payments of up to $255.0 million [5]

Core Insights - Garrett Motion Inc. will host its 2026 Technology and Investor Day in New York City on May 20, 2026, to discuss its strategic evolution and financial priorities [1][2]. Group 1: Event Details - The event will feature presentations, technology demonstrations, and discussions on the company's Turbo, Zero-Emission Vehicle, and Industrial technology portfolios [2]. - Presentations will start at 9:00 a.m. ET, followed by an interactive exhibition showcasing select technologies [3]. Group 2: Company Overview - Garrett Motion has a 70-year history of innovation in the automotive sector and beyond, with expertise in turbocharging that reduces engine size, fuel consumption, and CO2 emissions [4]. - The company operates six R&D centers and 13 manufacturing facilities, employing approximately 8,700 people across more than 20 countries [4].

Core Viewpoint - Lithium Ionic Corp. has secured multi-year offtake agreements with Yahua Group and Grand Chen for the supply of spodumene concentrate from its Bandeira Lithium Project, which is a significant step towards project financing and construction decision [1][3]. Group 1: Offtake Agreements - The agreements are for a total supply of 170,000 tonnes per annum of spodumene concentrate over five years, with a minimum price of US$1,000 per tonne and no maximum price limit, ensuring full exposure to lithium price upside [6]. - Pricing is indexed to prevailing market prices with no discount to the applicable market reference price, reflecting the strength and expected commercial quality of the Bandeira Project [6]. Group 2: Financial Support - Yahua Group and Grand Chen have agreed to provide a combined US$20 million in pre-payment facilities, which will align with the advancement of the Bandeira Project towards a construction decision [5][6]. Group 3: Strategic Importance - The partnerships with Yahua Group and Grand Chen, both established players in the lithium supply chain, provide strong validation of the Bandeira Project's quality and strategic importance in the growing global lithium market [3][4]. - These companies have existing relationships with members of the Lithium Ionic development team, which supports efficient execution as the project advances [4].

Core Viewpoint - Picard Medical, Inc. experienced a transformational year in 2025, marked by revenue growth, improved operating performance, and a strengthened balance sheet following its public listing and capital raises [1][3]. Financial Results - Total revenue for 2025 was $4.94 million, an increase of 12.5% from $4.39 million in 2024 [4][8]. - Product revenue accounted for $4.75 million, while rental revenue was $0.19 million, driven by the adoption of the SynCardia Total Artificial Heart [4]. - Gross loss was $(0.2) million, with a gross margin of (4.1%), compared to a gross loss of $(0.1) million and a margin of (2.6%) in 2024 [5][8]. - Operating expenses were $13.1 million, a decrease from $13.6 million in 2024, with R&D expenses at $3.0 million and SG&A expenses at $10.0 million [6][8]. - Operating loss was $(13.3) million, slightly improved from $(13.7) million in 2024 [7][8]. - Net loss for the year was $(27.0) million, compared to $(21.1) million in 2024 [9][8]. Liquidity and Capital Resources - Cash, cash equivalents, and restricted cash totaled $11.5 million as of December 31, 2025, a significant increase from $0.1 million at the end of 2024 [10]. - Net cash used in operating activities was $(15.7) million, while net cash provided by financing activities was $27.1 million [10]. Outlook - The company plans to continue investing in commercialization, manufacturing scale, and product development, indicating that additional capital will be required to support operations and execute its business plan [11]. About Picard Medical and SynCardia - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which leads in total artificial heart technology for patients with end-stage heart failure. The SynCardia Total Artificial Heart is the first artificial heart approved by both the FDA and Health Canada, with over 2,100 implants performed globally [12].

Core Insights - Winnebago Industries, Inc. reported strong financial performance for the second quarter of Fiscal 2026, with net revenues of $657.4 million, a 6.0% increase from $620.2 million in the same quarter of Fiscal 2025, driven by selective price adjustments and product mix [7][9] - The company redeemed $100 million of its outstanding Senior Secured Notes, enhancing its balance sheet and demonstrating a commitment to financial strength [5][17] - Winnebago maintains its Fiscal 2026 guidance for revenue and adjusted earnings per share (EPS), reflecting confidence in operational execution and market positioning despite macroeconomic uncertainties [2][19] Financial Performance - Gross profit for the second quarter was $85.6 million, up 2.9% from $83.1 million in the prior year, with a gross profit margin of 13.0%, down 40 basis points [8][9] - Operating income improved significantly by 50.7% to $11.8 million from $7.8 million in the second quarter of Fiscal 2025, while net income was $4.8 million, or $0.17 per diluted share, compared to a net loss of $0.4 million in the prior year [9][30] - Adjusted EBITDA for the quarter was $24.4 million, a 7.0% increase year-over-year, indicating improved operational efficiency [10][49] Segment Performance - The Motorhome RV segment saw net revenues increase by 29.3% to $304.7 million, with operating income turning positive at $7.5 million compared to a loss of $0.6 million in the previous year [12][41] - The Towable RV segment experienced a decline in net revenues by 9.0% to $262.4 million, with operating income decreasing by 12.2% [11][38] - The Marine segment reported a slight decrease in net revenues by 3.0% to $79.2 million, with a significant drop in operating income by 46.2% [13][43] Balance Sheet and Cash Flow - As of February 28, 2026, cash and cash equivalents totaled $47.4 million, down from $181.7 million at the end of the first quarter of Fiscal 2026, primarily due to the debt redemption [14][17] - Total outstanding debt was $442.3 million, with a gross leverage ratio improving to 3.2x from 4.0x as of November 29, 2025 [17][19] - Working capital decreased to $403.5 million from $465.1 million at the end of Fiscal 2025, reflecting changes in inventory and receivables [17][31] Outlook - For calendar year 2026, Winnebago expects North American RV wholesale shipments to range between 315,000 to 345,000 units, maintaining its revenue and adjusted EPS guidance [19][24] - The company emphasizes disciplined execution and product innovation as key strategies to navigate market volatility and enhance growth prospects [20][19]

VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) -- Westhaven Gold Corp. (TSX-V: WHN) (OTCQB: WTHVF) (“Westhaven” or the “Company”) is pleased to announce that it has entered into an initial three-month investor relations agreement, effective April 1, 2026, with San Diego Torrey Hills Capital ("SDTHC"), a U.S.-based investor relations and corporate communications firm. Under the terms of the agreement, the Company will pay SDTHC a monthly cash fee of US$7,000 and will reimburse certain expenses ...